Wayne Biosciences

Wayne Biosciences is a clinical-stage biotechnology company focused on the discovery and development of innovative therapies for metabolic and endocrine diseases. The company specializes in developing next-generation multi-agonist peptides and small molecules targeting the GLP-1, GIP, and glucagon receptors to treat conditions such as obesity, type 2 diabetes, and MASH (formerly NASH). Wayne Biosciences leverages its expertise in peptide engineering and metabolic biology to create differentiated treatments with improved efficacy and safety profiles. Headquartered in China, the company is advancing a robust pipeline of candidates through early-stage clinical trials to address significant unmet medical needs in the global metabolic health market.